Literature DB >> 12095149

Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase.

Shinichiro Okamoto1, Reiko Watanabe, Satoshi Takahashi, Takehiko Mori, Tohru Izeki, Hitomi Nagayama, Akaru Ishida, Nobuyuki Takayama, Kenji Yokoyama, Arinobu Tojo, Shigetaka Asano, Yasuo Ikeda.   

Abstract

Although allogeneic transplantation is a curative therapy for chronic myelogenous leukemia (CML), treatment-related mortality is still a major cause of death after transplantation, especially in older patients. We investigated the safety and efficacy of reduced-intensity conditioning consisting of low-dose (600 cGy) total body irradiation and cytosine arabinoside (1 g/m2) together with a continuous infusion of granulocyte colony-stimulating factor and cyclophosphamide (120 mg/kg) in patients with CML in the chronic phase. Fractionated splenic irradiation (5 Gy) was also administered as part of the conditioning treatment. Eight patients older than 40 years underwent allogeneic bone marrow transplantation from an HLA-matched sibling following this conditioning. Regimen-related toxicities (equal to or greater than grade III) were not observed. Rapid restoration of 100% donor chimerism was confirmed by fluorescence in situ hybridization methods in 5 sex-mismatched transplant recipients. One patient died from severe acute graft-versus-host disease and another from Pneumocystis carinii pneumonia early in the course of transplantation. A sustained engraftment was achieved in 5 long-term survivors; in 1 case, the graft was rejected but the Philadelphia chromosome and BCR/ABL-negative autologous hemopoiesis were restored. After a minimum follow-up period of 60 months, 6 patients, including the patient with restored autologous hemopoiesis, were still alive and in remission with 100% donor chimerism. Six years after the transplantation, 1 patient experienced a cytogenetic relapse, which was successfully treated with donor lymphocyte infusions. In summary, this reduced-intensity conditioning resulted in a cure with markedly reduced regimen-related toxicities in this relatively older cohort of patients with CML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095149     DOI: 10.1007/bf02982112

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Authors:  R Storb; C Yu; J L Wagner; H J Deeg; R A Nash; H P Kiem; W Leisenring; H Shulman
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

2.  Early detection of bone marrow engraftment by amplification of hypervariable DNA regions.

Authors:  G Martinelli; E Trabetti; P Farabegoli; N Testoni; G Bandini; M R Motta; A Vittone; C Terragna; P F Pignatti; S Tura
Journal:  Haematologica       Date:  1997 Mar-Apr       Impact factor: 9.941

3.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

4.  Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen.

Authors:  H Khoury; D Adkins; R Brown; H Pence; R Vij; L T Goodnough; P Westervelt; K Trinkaus; H S Lin; Y DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

5.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

Authors:  C Cutler; S Giri; S Jeyapalan; D Paniagua; A Viswanathan; J H Antin
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

7.  Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Authors:  A Gratwohl; J Hermans; A van Biezen; W Arcese; L Debusscher; P Ernst; A Ferrant; F Frassoni; G Gahrton; A Iriondo; H J Kolb; H Link; D Niederwieser; T Ruutu; W Siegert; F E Zwaan
Journal:  Br J Haematol       Date:  1996-12       Impact factor: 6.998

8.  Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.

Authors:  H Brincker
Journal:  Scand J Haematol       Date:  1982-09

9.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  A Gratwohl; J Hermans; J M Goldman; W Arcese; E Carreras; A Devergie; F Frassoni; G Gahrton; H J Kolb; D Niederwieser; T Ruutu; J P Vernant; T de Witte; J Apperley
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

10.  Fluorescence in situ hybridization with X and Y chromosome probes for cytogenetic studies on bone marrow cells after opposite sex transplantation.

Authors:  G W Dewald; C R Schad; E R Christensen; M E Law; A R Zinsmeister; P G Stalboerger; S M Jalal; R C Ash; R B Jenkins
Journal:  Bone Marrow Transplant       Date:  1993-08       Impact factor: 5.483

View more
  1 in total

Review 1.  The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.

Authors:  Corey Cutler; Joseph H Antin
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.